SOURCE: MarketResearch.com

MarketResearch.com

January 18, 2011 08:08 ET

Oncotype Dx for Breast Cancer Expected to Reach $300 Million by 2015

ROCKVILLE, MD--(Marketwire - January 18, 2011) -  MarketResearch.com has announced the addition of BCC Research's new report "Companion Diagnostics: Technologies and Global Markets" to their collection of In Vitro Diagnostics market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6003160

When the human genome project was finally completed in 2003, the idea of testing the specific genetic signature for every human individual became a reality. In addition to the fast development of proteomic approaches and array technology, a new trend in personalized medicine started to evolve as part of the healthcare system. Personalized medicine became more and more embraced by healthcare providers, the pharmaceutical industry and even insurance companies, in an attempt to reduce unnecessary expenses and costs for patients' treatments. Indeed, a new organization was formed called the Personalized Medicine Coalition (PMC), a nonprofit advocacy group that keeps close track of all the recent developments and propositions in this field.

Companion diagnostics is part of the "personalized medicine revolution." The field evolved as a continuation of biomarker studies and diagnostics testing. And although this area of industry is still young, it becomes more and more complicated and developed, with a number of successful FDA-approved products.

Oncotype Dx, although not FDS-approved, is still a lead product in the breast cancer diagnosis sector. Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year. Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.

The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6003160

Contact Information